Background: The novel coronavirus known as SARS-CoV-2 has spread worldwide and caused the COVID-19 pandemic. In September 2020, more than 32 million confirmed cases of COVID-19, with a death toll of more than 990,000. Among COVID-19 patients, those with cancer had worse outcomes than those without malignancy, but in some studies, the mortality rates differed significantly, ranging from 3.7% to 61.5%. Method: In this descriptive study, survival analysis with the Kaplan Meier curve was used to determine the healing rate of patients with cancer exposed to COVID-19 and undergoing treatment at dr. Moewardi General Hospital Surakarta-Indonesia from February to December 2020, and the Log Rank test was used to analyze data on two related groups. Results: The analysis using the Kaplan Meier method, female patients were found to have a higher survival rate than females, paged <50 years had a higher survival rate than those aged > 51 years, breast cancer had the lowest survival rate, and comorbidity of anemia had a higher survival rate than those with other comorbidities. The Log Rank test found a significant difference in the cumulative survival rates of cancer patients with COVID-19 with a p-value of 0.010 for comorbidity types. Meanwhile, from gender (p = 0.632), age (p = 0.672), type of cancer (p = 0.472), there was no significant difference. Conclusion: COVID-19 female patients aged less than 50 years with types of malignancy other than breast cancer and comorbidity of anemia have a higher survival rate.